Follow CGSP on Social Media

Listen to the CGSP Podcast

India Moves to Challenge China’s Emerging Dominance in C19 Vaccine Distribution in Developing Countries

Workers unload boxes containing Covishield, AstraZeneca's Covid-19 coronavirus vaccine made by India's Serum Institute, upon its arrival from India at the health center in Kathmandu on January 21, 2021. PRAKASH MATHEMA / AFP

Developing countries in Southeast Asia, Africa, and the Americas are now the new front in an increasingly contentious struggle between Asia’s two continental powers. India and China, both pharmaceutical manufacturing powerhouses, are jostling over who will become the primary supplier of COVID-19 vaccines to many of the world’s poorest countries.

The Serum Institute of India (SII), the world’s largest vaccine manufacturer, is producing vaccines in collaboration with the University of Oxford and AstraZeneca, and in just the past few days the company’s shipped tens of millions of doses to Bhutan, Nepal, Bangladesh, Maldives, Myanmar, Mauritius, and Seychelles.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.